UNICREDIT BANK/CALL/ELI LILLY & CO/1200/0.1/19.03.25 Stock

Warrant

DE000HD43W84

Real-time Bid/Ask 04:06:16 2024-05-23 EDT
1.28 EUR / 1.53 EUR +6.44% Intraday chart for UNICREDIT BANK/CALL/ELI LILLY & CO/1200/0.1/19.03.25
Current month+46.67%
1 month+21.10%
Date Price Change
24-05-23 1.27 -3.79%
24-05-22 1.32 +33.33%
24-05-21 0.99 -10.81%
24-05-20 1.11 +8.82%
24-05-17 1.02 -6.42%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 03:24 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HD43W8
ISINDE000HD43W84
Date issued 2024-03-25
Strike 1,200 $
Maturity 2025-03-19 (301 Days)
Parity 10 : 1
Emission price 2.01
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.83
Lowest since issue 0.78
Delta0.14x
Omega 7.457
Premium51.36x
Gearing52.4x
Moneyness 0.6691
Difference Strike 397.1 $
Difference Strike %+33.09%
Spread 0.25
Spread %16.23%
Theoretical value 1.415
Implied Volatility 32.74 %
Total Loss Probability 91.37 %
Intrinsic value 0.000000
Present value 1.415
Break even 1,215.32 €
Theta-0.07x
Vega0.15x
Rho0.08x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9 USD
Average target price
850.4 USD
Spread / Average Target
+5.92%
Consensus